about
Multiparametric monitoring of chemotherapy treatment response in locally advanced breast cancer using quantitative ultrasound and diffuse optical spectroscopyAdvanced MRI in malignant neoplasms of the uterus.Lectin conjugates as biospecific contrast agents for MRI. Coupling of Lycopersicon esculentum agglutinin to linear water-soluble DTPA-loaded oligomers.Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors.Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancerMolecular imaging in oncology.Preoperative staging of colorectal cancer--computed tomography and magnetic resonance imaging.The role of functional and molecular imaging in cancer drug discovery and development.Molecular imaging in vivo: an introduction.Imaging angiogenesis: applications and potential for drug development.Diffusion-weighted magnetic resonance imaging in predicting the radiosensitivity of cervical cancer.Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?Functional imaging for assessing tumor response in cancer of the cervix.Efficacy of positive contrast imaging techniques for molecular MRI of tumor angiogenesis.Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights.Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma.Diffusion-weighted MRI in early assessment of tumour response to radiotherapy in high-risk prostate cancer.Use of Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovasculari- zation as well as Tumor Cells in Molecular Tumor ImagingOptimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology.Pelvic malignancy: integrating form and function.Comparative study of methods for determining vascular permeability and blood volume in human gliomas.Gadolinium-labeled quantum dots for molecular magnetic resonance imaging: R1 versus R2 mappingRegional heterogeneity changes in DCE-MRI as response to isolated limb perfusion in experimental soft-tissue sarcomas
P2860
Q30375438-5FF71518-3E32-411A-9984-3A5F283B7287Q30586370-F0F94C94-D91C-4CD2-BE33-C3728F9AC7EDQ33614876-607C59DA-132A-49E7-9433-A10EF58ECFCBQ33760493-8DB0F9BC-AD73-451B-8FE0-DF49992B8B3CQ34390068-A295DE32-6353-4402-8B4F-05D99FA1FE82Q34533365-B3C5C8AF-A949-4E52-B08F-340A2A95DA95Q35111164-2CC276A9-67AE-42DC-84A6-426C22B21306Q35968111-8F3565B4-D03F-4D4E-B7A6-5CB7A47E69C6Q35968130-AFC10D7E-B789-471E-AB06-F15025FAB95DQ36027611-7B23A561-041B-44CD-9D68-200B86C966EEQ36183307-ED5A16E1-ED63-46A6-9B8F-A8694834BA50Q36694909-577754A4-F232-44DA-96D0-24AD50B3C3E9Q37905821-DB695E0D-911D-4F97-953E-BEF80EE0AF74Q39376149-378BC21C-90C3-4FDB-B656-710A3A1B8452Q39543749-6A8FE046-17CB-489E-AAAD-BADC034A3E0DQ40510307-3F43931C-9F27-455D-B6E5-5E93770F310AQ41881716-43875B76-9D7D-4F49-AEDD-866678779A52Q42573080-600FB299-85DB-4B10-9A54-995998D3ECF4Q43248494-8D454CF9-866E-433C-93FE-30AE0F552E59Q45822086-36F0A3F9-51B7-43A6-AAD1-EF24BDB2EBE2Q53562438-415EEA1A-CA93-48F2-91FE-F6BD514D3C15Q55471802-12F08A68-F009-4863-A44A-F4375FCE457CQ57185629-699A4BF7-734D-4398-99DF-A6F6DD7407D6Q57719785-6E4DC4AC-B26B-414F-ABC4-EC060F789264
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Functional MRI for anticancer therapy assessment.
@ast
Functional MRI for anticancer therapy assessment.
@en
Functional MRI for anticancer therapy assessment.
@nl
type
label
Functional MRI for anticancer therapy assessment.
@ast
Functional MRI for anticancer therapy assessment.
@en
Functional MRI for anticancer therapy assessment.
@nl
prefLabel
Functional MRI for anticancer therapy assessment.
@ast
Functional MRI for anticancer therapy assessment.
@en
Functional MRI for anticancer therapy assessment.
@nl
P1476
Functional MRI for anticancer therapy assessment.
@en
P2093
Padhani AR
P304
P356
10.1016/S0959-8049(02)00388-X
P577
2002-11-01T00:00:00Z